SEARCH

SEARCH BY CITATION

References

  • Adams S. M., De Rivero Vaccari J. C. and Corriveau R. A. (2004) Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J. Neurosci. 24, 94419450.
  • Anastasio N. C. and Johnson K. M. (2008) Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol. Biochem. Behav. 90, 569577.
  • Bandyopadhyay S., Gonzalez-Islas C. and Hablitz J. J. (2005) Dopamine enhances spatiotemporal spread of activity in rat prefrontal cortex. J. Neurophysiol. 93, 864872.
  • Du Bois T. M. and Huang X. F. (2007) Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res. Rev. 53, 260270.
  • Bortolato M., Aru G. N., Fa M. et al. (2005) Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle. Neuropsychopharmacology 30, 561574.
  • Braff D. L., Geyer M. A. and Swerdlow N. R. (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156, 234258.
  • Braithwaite S. P., Adkisson M., Leung J., Nava A., Masterson B., Urfer R., Oksenberg D. and Nikolich K. (2006) Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP). Eur. J. Neurosci. 23, 28472856.
  • Broberg B. V., Dias R., Glenthoj B. Y. and Olsen C. K. (2008) Evaluation of a neurodevelopmental model of schizophrenia--early postnatal PCP treatment in attentional set-shifting. Behav. Brain Res. 190, 160163.
  • Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M. and Carlsson M. L. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237260.
  • Cepeda C., Buchwald N. A. and Levine M. S. (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl Acad. Sci. USA 90, 95769580.
  • Chen G., Greengard P. and Yan Z. (2004) Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc. Natl Acad. Sci. USA 101, 25962600.
  • Cull-Candy S. G. and Leszkiewicz D. N. (2004) Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE 2004, re16.
  • Curzon P. and Decker M. W. (1998) Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 129146.
  • Dunah A. W. and Standaert D. G. (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21, 55465558.
  • Dunah A. W., Sirianni A. C., Fienberg A. A., Bastia E., Schwarzschild M. A. and Standaert D. G. (2004) Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol. Pharmacol. 65, 121129.
  • Duncan G. E., Moy S. S., Lieberman J. A. and Koller B. H. (2006) Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol. Biochem. Behav. 85, 481491.
  • Elvevag B. and Goldberg T. E. (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 121.
  • Emamian E. S., Karayiorgou M. and Gogos J. A. (2004) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J. Neurosci. 24, 15611564.
  • Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C. R., Jokel E. S., Fienberg A. A., Greengard P. and Levine M. S. (2002) Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 88, 30103020.
  • Gao C. and Wolf M. E. (2008) Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J. Neurochem. 106, 24892501.
  • Geyer M. A., Krebs-Thomson K., Braff D. L. and Swerdlow N. R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156, 117154.
  • Gonzalez-Islas C. and Hablitz J. J. (2003) Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex. J. Neurosci. 23, 867875.
  • Greengard P. (2001) The neurobiology of dopamine signaling. Biosci. Rep. 21, 247269.
  • Groc L., Choquet D., Stephenson F. A., Verrier D., Manzoni O. J. and Chavis P. (2007) NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. J. Neurosci. 27, 1016510175.
  • Hallett P. J., Spoelgen R., Hyman B. T., Standaert D. G. and Dunah A. W. (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci. 26, 46904700.
  • Hardingham G. E., Fukunaga Y. and Bading H. (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405414.
  • Heresco-Levy U., Ermilov M., Giltsinsky B., Lichtenstein M. and Blander D. (1999) Treatment-resistant schizophrenia and staff rejection. Schizophr. Bull. 25, 457465.
  • Ikonomidou C., Bosch F., Miksa M. et al. (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 7074.
  • Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y. and Medina I. (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 572, 789798.
  • Javitt D. C. (2001) Management of negative symptoms of schizophrenia. Curr Psychiatry Rep 3, 413417.
  • De Jong I. E. and Van Den Buuse M. (2006) SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology 51, 438446.
  • Kargieman L., Santana N., Mengod G., Celada P. and Artigas F. (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl Acad. Sci. USA 104, 1484314848.
  • Lee F. J., Xue S., Pei L. et al. (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111, 219230.
  • Lei G., Xia Y. and Johnson K. M. (2008) The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology 33, 13431353.
  • McGhie A. and Chapman J. (1961) Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34, 103116.
  • Monti B. and Contestabile A. (2000) Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum. Eur. J. Neurosci. 12, 31173123.
  • Mouri A., Noda Y., Noda A., Nakamura T., Tokura T., Yura Y., Nitta A., Furukawa H. and Nabeshima T. (2007) Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol. Pharmacol. 71, 15981609.
  • Nakazawa T., Komai S., Tezuka T., Hisatsune C., Umemori H., Semba K., Mishina M., Manabe T. and Yamamoto T. (2001) Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 276, 693699.
  • Neve K. A., Seamans J. K. and Trantham-Davidson H. (2004) Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165205.
  • Olney J. W. and Farber N. B. (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13, 335345.
  • Olney J. W., Newcomer J. W. and Farber N. B. (1999) NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33, 523533.
  • Papadia S., Soriano F. X., Leveille F. et al. (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11, 476487.
  • Prybylowski K., Chang K., Sans N., Kan L., Vicini S. and Wenthold R. J. (2005) The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47, 845857.
  • Salter M. W. and Kalia L. V. (2004) Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5, 317328.
  • Scott D. B., Blanpied T. A., Swanson G. T., Zhang C. and Ehlers M. D. (2001) An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J. Neurosci. 21, 30633072.
  • Seamans J. K., Durstewitz D., Christie B. R., Stevens C. F. and Sejnowski T. J. (2001) Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc. Natl Acad. Sci. USA 98, 301306.
  • Shim S. S., Hammonds M. D. and Kee B. S. (2008) Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur. Arch. Psychiatry Clin. Neurosci. 258, 1627.
  • Slikker Jr W., Zou X., Hotchkiss C. E. et al. (2007) Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol Sci 98, 145158.
  • Snyder G. L., Fienberg A. A., Huganir R. L. and Greengard P. (1998) A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18, 1029710303.
  • Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 10511058.
  • Soriano F. X., Papadia S., Hofmann F., Hardingham N. R., Bading H. and Hardingham G. E. (2006) Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J. Neurosci. 26, 45094518.
  • Sun X., Zhao Y. and Wolf M. E. (2005) Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J. Neurosci. 25, 73427351.
  • Suzuki T. and Okumura-Noji K. (1995) NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216, 582588.
  • Tingley W. G., Ehlers M. D., Kameyama K., Doherty C., Ptak J. B., Riley C. T. and Huganir R. L. (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272, 51575166.
  • Tseng K. Y. and O’Donnell P. (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 24, 51315139.
  • Wang C. Z. and Johnson K. M. (2007) The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32, 11781194.
  • Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J. L. and Johnson K. M. (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107, 535550.
  • Williams G. V. and Goldman-Rakic P. S. (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572575.
  • Yang S. N. (2000) Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: an essential role of postsynaptic Ca2+. Hippocampus 10, 5763.
  • Yang C. R. and Chen L. (2005) Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 11, 452470.